BBIO · BridgeBio Pharma, Inc. · Documents

Jun 23

Current report 8-K Events of Jun 20

Change to shareholders' rights, Charter or bylaw amendment, or fiscal year change, Shareholder vote results

May 9

Proxy statement DEFA14A

Proxy statement

Apr 30

Proxy statement DEF 14A Meeting Jun 20, 2025

Proxy statement

Apr 30

Proxy statement DEFA14A

Proxy statement

Apr 30

Annual report to holders ARS

Annual report to holders

Apr 29

Earnings call

Q1 2025 earnings call

Apr 29

Current report 8-K

Financial results

Apr 29

Quarterly report 10-Q FY2025 Q1, ended Mar 31

Quarterly report for FY2025 Q1

Revenue $116.63M ▼ 44.8% Net loss $169.61M Diluted EPS -$0.88

Apr 16

Proxy statement PRE 14A Meeting Jun 20, 2025

Proxy statement

Mar 17

Current report 8-K

Director or officer change, or executive pay, Regulation FD disclosure

Feb 28

Current report 8-K Events of Feb 24

Entered into a material agreement, Ended a material agreement, New debt or off-balance-sheet obligation, Unregistered sale of equity, Other events

Feb 20

Current report 8-K

Financial results

Feb 20

Annual report 10-K FY2024, ended Dec 31

Annual report for FY2024

Revenue $221.9M ▲ 2285.3% Net loss $543.35M Diluted EPS -$2.88

Jan 13

Current report 8-K

Financial results, Regulation FD disclosure, Other events

Nov 25

Current report 8-K Events of Nov 22

Other events

Nov 12

Current report 8-K

Financial results

Nov 12

Quarterly report 10-Q FY2024 Q3, ended Sep 30

Quarterly report for FY2024 Q3

Revenue $2.73M ▼ 33.2% Net loss $164.25M Diluted EPS -$0.86

Sep 11

Current report 8-K Events of Sep 10

Other events

Aug 21

Current report 8-K Events of Aug 16

Entered into a material agreement

Aug 1

Current report 8-K

Financial results

Aug 1

Quarterly report 10-Q FY2024 Q2, ended Jun 30

Quarterly report for FY2024 Q2

Revenue $2.17M ▲ 32.1% Net loss $75.54M Diluted EPS -$0.39

Jul 23

Current report 8-K

Director or officer change, or executive pay, Regulation FD disclosure

Jun 24

Current report 8-K Events of Jun 21

Shareholder vote results

Jun 6

Current report 8-K Events of Jun 4

Other events

May 2

Current report 8-K

Financial results

May 2

Quarterly report 10-Q FY2024 Q1, ended Mar 31

Quarterly report for FY2024 Q1

Revenue $211.12M ▲ 11461.9% Net loss $36.16M Diluted EPS -$0.20

Apr 25

Proxy statement DEF 14A Meeting Jun 21, 2024

Proxy statement

Apr 25

Annual report to holders ARS

Annual report to holders

Apr 25

Proxy statement DEFA14A

Proxy statement

Mar 6

Current report 8-K Events of Mar 5

Entered into a material agreement, Other events

Mar 4

Current report 8-K Events of Mar 1

Entered into a material agreement

Feb 22

Current report 8-K

Financial results

Feb 22

Annual report 10-K FY2023, ended Dec 31

Annual report for FY2023

Revenue $9.3M ▼ 88.0% Net loss $653.25M Diluted EPS -$3.95

Jan 18

Current report 8-K Events of Jan 17

Entered into a material agreement, Ended a material agreement, New debt or off-balance-sheet obligation

Jan 8

Current report 8-K

Other events

Nov 2

Current report 8-K

Financial results

Nov 2

Quarterly report 10-Q FY2023 Q3, ended Sep 30

Quarterly report for FY2023 Q3

Revenue $4.09M ▲ 1110.4% Net loss $179.49M Diluted EPS -$1.08

Nov 2

Registration statement S-3ASR

Registration statement

Sep 25

Current report 8-K

Entered into a material agreement, Unregistered sale of equity, Regulation FD disclosure

Aug 3

Current report 8-K

Financial results

Aug 3

Quarterly report 10-Q FY2023 Q2, ended Jun 30

Quarterly report for FY2023 Q2

Revenue $1.64M ▼ 97.8% Net loss $160.7M Diluted EPS -$0.98

Jul 26

Registration statement S-3ASR

Registration statement

Jul 17

Current report 8-K

Regulation FD disclosure, Other events

Jun 22

Current report 8-K Events of Jun 21

Shareholder vote results

May 4

Current report 8-K

Financial results

May 4

Current report 8-K Events of May 3

Entered into a material agreement, Ended a material agreement

May 4

Quarterly report 10-Q FY2023 Q1, ended Mar 31

Quarterly report for FY2023 Q1

Revenue $1.83M ▲ 7.8% Net loss $142.73M Diluted EPS -$0.92

May 4

Registration statement S-3ASR

Registration statement

Apr 28

Proxy statement DEF 14A

Proxy statement

Apr 28

Annual report to holders ARS

Annual report to holders